14 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2.
University of Texas Southwestern Medical Center
Development of inhibitors of the PAS-B domain of the HIF-2a transcription factor.
University of Texas Southwestern Medical Center
Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges.
National Cancer Institute-Frederick
Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2a induced gene expression.
Nci-Frederick
Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009-2024).
Hubei Polytechnic University
Identification of 3-aryl-5-methyl-isoxazole-4-carboxamide derivatives and analogs as novel HIF-2α agonists through docking-based virtual screening and structural modification.
Zhejiang University
Discovery of a Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α (HIF-2α) Agonist and Its Synergistic Therapy with Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia.
China Pharmaceutical University
Inhibitors of Hypoxia-Inducible Factors as Treatment for Cancer.
Therachem Research Medilab
Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).
Peloton Therapeutics
PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT
Hana Pharm